肌肉骨骼超声对疑似风湿性多肌痛的诊断准确性:多中心队列研究
该多中心诊断准确性研究在荷兰Groningen回顾性队列(92例)和丹麦Aarhus前瞻性队列(93例)中评估肌肉骨骼超声对疑似风湿性多肌痛的诊断价值。结果显示无单一超声发现具有病理特异性;至少一个炎症病变敏感性高(93%和92%),肩髋带同时受累特异性高(85%和93%)。超声阴性使诊断可能性降低,但阳性需结合临床谨慎评估。
要点
- 无单一肌肉骨骼超声发现对风湿性多肌痛具有病理特异性。
- 至少一个炎症病变的敏感性在Groningen队列为93%,Aarhus队列为92%。
- 肩带和髋带同时至少一个炎症病变的特异性分别为85%和93%。
核心结论
- 超声上肩带和髋带无病变使风湿性多肌痛诊断可能性降低,但病变存在时需谨慎临床评估,因其他炎症性风湿病也可出现类似表现。
- 肌肉骨骼超声可作为疑似风湿性多肌痛临床评估的潜在辅助手段。
研究设计与样本
- 多中心诊断准确性研究,纳入连续、未使用糖皮质激素的疑似风湿性多肌痛患者。
- Groningen回顾性队列92例(男性41例[45%],女性51例[55%],平均年龄69岁[SD 9]),参考标准为6个月随访后临床诊断。
- Aarhus前瞻性队列93例(男性53例[57%],女性40例[43%],平均年龄71岁[SD 8]),参考标准为12个月随访后临床诊断。
主要发现
- Groningen队列58例(63%)在6个月随访后诊断为风湿性多肌痛,Aarhus队列66例(71%)在12个月时诊断为风湿性多肌痛。
- 至少一个炎症病变(Groningen 10部位计数,Aarhus 6部位计数)敏感性最高:Groningen 93%(95% CI 83-98),Aarhus 92%(95% CI 83-98)。
- 肩带和髋带同时至少一个炎症病变特异性最高:Groningen 85%(95% CI 69-95),Aarhus 93%(95% CI 76-99)。
- 肌肉骨骼超声区分风湿性多肌痛与非炎症性疾病的能力优于区分其他炎症性风湿病。
关键数值与推荐
- Groningen队列评估肩峰下-三角肌下滑囊炎、肱二头肌腱鞘炎、髋关节滑膜炎、盂肱关节滑膜炎和转子滑囊炎,计算10部位风湿性多肌痛超声病变计数。
- Aarhus队列评估肩峰下-三角肌下滑囊炎、肱二头肌腱鞘炎和髋关节滑膜炎,计算6部位风湿性多肌痛超声病变计数。
临床怎么用
- 对疑似风湿性多肌痛患者,超声肩带和髋带无炎症病变可降低诊断可能性。
- 超声发现炎症病变时需结合临床评估,因其他炎症性风湿病也可有类似表现。
- 肌肉骨骼超声可作为临床评估的辅助手段用于疑似风湿性多肌痛的诊断。
局限性
- Groningen队列为回顾性设计,且未应用明确的转诊标准。
- Aarhus队列排除了有巨细胞动脉炎颅部症状、过去5年内癌症或已有炎症性风湿病的患者。
- 研究设计或实施未纳入患者生活经验参与。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diagnosing polymyalgia rheumatica is challenging, and musculoskeletal ultrasound is primarily used in diagnostically difficult situations. Previous musculoskeletal ultrasound studies in patients with polymyalgia rheumatica used case-control designs or non-representative cohorts, reducing assessment of diagnostic accuracy. This study aimed to assess the diagnostic accuracy of musculoskeletal ultrasound in two independent cohorts of patients with suspected polymyalgia rheumatica. METHODS: This multicentre, diagnostic accuracy study included consecutive, glucocorticoid-naive patients with suspected polymyalgia rheumatica, referred for rheumatology evaluation at the University Medical Center Groningen, the Netherlands (retrospective cohort), between April 30, 2019, and Feb 13, 2024, and at Aarhus University Hospital, Silkeborg Regional Hospital, and Horsens Regional Hospital, Denmark (prospective cohort), between Sept 14, 2020, and June 30, 2022. The Aarhus cohort included patients older than 50 years with proximal muscle or joint pain and excluded patients with cranial symptoms suggestive of giant cell arteritis, cancer within the past 5 years, or pre-existing inflammatory rheumatic disease. No explicit referral criteria were applied in the Groningen cohort. Participants underwent protocolised clinical examination and musculoskeletal ultrasound. The reference standard was clinical diagnosis after 6 months (Groningen) or 12 months (Aarhus) of follow-up. Musculoskeletal ultrasound assessment included subacromial-subdeltoid bursitis, biceps tenosynovitis, and hip synovitis in both cohorts, plus glenohumeral synovitis and trochanteric bursitis in the Groningen cohort. A polymyalgia rheumatica ultrasound lesion count was calculated based on six (Aarhus) and ten (Groningen) sites. Diagnostic performance of individual and combined lesions was assessed using sensitivity, specificity, likelihood ratios, and receiver operating characteristic (ROC) analysis. There was no lived experience involvement in the study design or conduct. The Aarhus cohort study is registered with ClinicalTrials.gov, NCT04519580. FINDINGS: The Groningen cohort included 92 patients patients with suspected polymyalgia rheumatica (41 [45%] male, 51 [55%] female, mean age 69 years [SD 9]), of whom 58 (63%) were diagnosed with polymyalgia rheumatica after 6-month follow-up. The Aarhus cohort included 93 patients (53 [57%] male, 40 [43%] female, mean age 71 years [SD 8]), 66 (71%) of whom had a diagnosis of polymyalgia rheumatica at 12 months. No single musculoskeletal ultrasound finding was pathognomonic for polymyalgia rheumatica. The combination of musculoskeletal ultrasound findings with the highest sensitivity was the presence of at least one inflammatory lesion (Groningen: 10-site polymyalgia rheumatica ultrasound lesion count 93% [95% CI 83-98]; Aarhus: 6-site polymyalgia rheumatica ultrasound lesion count 92% [83-98]). The combination with highest specificity was the presence of at least one inflammatory lesion in both the shoulder and hip girdles (Groningen: 85% [95% CI 69-95]; Aarhus: 93% [76-99]). ROC analysis showed an area under the curve of 0·779 (95% CI 0·675-0·883) for the 10-site count in Groningen and 0·769 (0·664-0·875) for the 6-site count in Aarhus. Musculoskeletal ultrasound performed better in distinguishing polymyalgia rheumatica from non-inflammatory conditions than from other inflammatory rheumatic diseases. INTERPRETATION: Absence of shoulder and hip lesions on musculoskeletal ultrasound makes a polymyalgia rheumatica diagnosis unlikely. However, their presence requires careful clinical evaluation, as similar findings occur in other inflammatory rheumatic diseases. These findings support the use of musculoskeletal ultrasound as a potential adjunct to clinical assessment when evaluating patients with suspected polymyalgia rheumatica. FUNDING: FOREUM, Danish Rheumatism Association, Independent Research Fund Denmark, Ketty and Ejvind Lyngsbæks Foundation, Frimodt-Heineke's Foundation, Aase and Ejnar Danielsen's Foundation, AP Møller Foundation, Health Research Foundation of Central Denmark Region, and Regional Hospital Central Jutland Research Foundation.
引用
- Våben CS, Nielsen AW, Sandovici M, et al. Diagnostic accuracy of musculoskeletal ultrasound in suspected polymyalgia rheumatica: a multicentre, cohort study. Lancet Rheumatol. 2026. PMID: 42767765. doi:10.1016/S2665-9913(26)00187-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。